Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor

Tomoaki Mori, Jun Sasaki, Yasuhiro Aoyama, Takashi Sera

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Repression of vascular endothelial growth factor A (VEGF-A) is an attractive approach to cancer therapy. Although zinc-finger-based artificial transcription factors (ATFs) were constructed for human VEGF-A and constitutive expressions of ATFs were previously shown to downregulate the endogenous VEGF-A gene expression, repression of VEGF-A specifically in hypoxic tumors is desirable for therapeutic application of ATF technology. Here, we describe hypoxia-driven expression of the ATF for hypoxia-specific repression of human VEGF-A gene. We constructed a hypoxia-driven promoter for the ATF expression and placed it upstream of the ATF-encoding region. The resulting hypoxia-driven expression plasmids induced the expression of ATFs specifically in hypoxia, and the hypoxia-specific expression of ATFs effectively downregulated the VEGF-A expression in hypoxia, but not in normoxia. Thus, the engineered expression system of ATFs may enable repression of VEGF-A expression specifically in hypoxic tumors without affecting normal, healthy tissues.

Original languageEnglish
Pages (from-to)134-139
Number of pages6
JournalMolecular Biotechnology
Volume46
Issue number2
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Transcription factors
Transcription Factors
Down-Regulation
Genes
Vascular Endothelial Growth Factor A
Tumors
Hypoxia
human VEGFA protein
Intercellular Signaling Peptides and Proteins
Neoplasms
Zinc Fingers
Gene expression
Zinc
Plasmids
Tissue
Technology
Gene Expression

Keywords

  • Artificial transcription factor
  • Cancer
  • Hypoxia
  • Hypoxia-response element
  • Vascular endothelial growth factor A
  • Zinc-finger protein

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor. / Mori, Tomoaki; Sasaki, Jun; Aoyama, Yasuhiro; Sera, Takashi.

In: Molecular Biotechnology, Vol. 46, No. 2, 10.2010, p. 134-139.

Research output: Contribution to journalArticle

@article{433bf8ec1ca24e5aa6da205303787020,
title = "Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor",
abstract = "Repression of vascular endothelial growth factor A (VEGF-A) is an attractive approach to cancer therapy. Although zinc-finger-based artificial transcription factors (ATFs) were constructed for human VEGF-A and constitutive expressions of ATFs were previously shown to downregulate the endogenous VEGF-A gene expression, repression of VEGF-A specifically in hypoxic tumors is desirable for therapeutic application of ATF technology. Here, we describe hypoxia-driven expression of the ATF for hypoxia-specific repression of human VEGF-A gene. We constructed a hypoxia-driven promoter for the ATF expression and placed it upstream of the ATF-encoding region. The resulting hypoxia-driven expression plasmids induced the expression of ATFs specifically in hypoxia, and the hypoxia-specific expression of ATFs effectively downregulated the VEGF-A expression in hypoxia, but not in normoxia. Thus, the engineered expression system of ATFs may enable repression of VEGF-A expression specifically in hypoxic tumors without affecting normal, healthy tissues.",
keywords = "Artificial transcription factor, Cancer, Hypoxia, Hypoxia-response element, Vascular endothelial growth factor A, Zinc-finger protein",
author = "Tomoaki Mori and Jun Sasaki and Yasuhiro Aoyama and Takashi Sera",
year = "2010",
month = "10",
doi = "10.1007/s12033-010-9288-z",
language = "English",
volume = "46",
pages = "134--139",
journal = "Molecular Biotechnology",
issn = "1073-6085",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor

AU - Mori, Tomoaki

AU - Sasaki, Jun

AU - Aoyama, Yasuhiro

AU - Sera, Takashi

PY - 2010/10

Y1 - 2010/10

N2 - Repression of vascular endothelial growth factor A (VEGF-A) is an attractive approach to cancer therapy. Although zinc-finger-based artificial transcription factors (ATFs) were constructed for human VEGF-A and constitutive expressions of ATFs were previously shown to downregulate the endogenous VEGF-A gene expression, repression of VEGF-A specifically in hypoxic tumors is desirable for therapeutic application of ATF technology. Here, we describe hypoxia-driven expression of the ATF for hypoxia-specific repression of human VEGF-A gene. We constructed a hypoxia-driven promoter for the ATF expression and placed it upstream of the ATF-encoding region. The resulting hypoxia-driven expression plasmids induced the expression of ATFs specifically in hypoxia, and the hypoxia-specific expression of ATFs effectively downregulated the VEGF-A expression in hypoxia, but not in normoxia. Thus, the engineered expression system of ATFs may enable repression of VEGF-A expression specifically in hypoxic tumors without affecting normal, healthy tissues.

AB - Repression of vascular endothelial growth factor A (VEGF-A) is an attractive approach to cancer therapy. Although zinc-finger-based artificial transcription factors (ATFs) were constructed for human VEGF-A and constitutive expressions of ATFs were previously shown to downregulate the endogenous VEGF-A gene expression, repression of VEGF-A specifically in hypoxic tumors is desirable for therapeutic application of ATF technology. Here, we describe hypoxia-driven expression of the ATF for hypoxia-specific repression of human VEGF-A gene. We constructed a hypoxia-driven promoter for the ATF expression and placed it upstream of the ATF-encoding region. The resulting hypoxia-driven expression plasmids induced the expression of ATFs specifically in hypoxia, and the hypoxia-specific expression of ATFs effectively downregulated the VEGF-A expression in hypoxia, but not in normoxia. Thus, the engineered expression system of ATFs may enable repression of VEGF-A expression specifically in hypoxic tumors without affecting normal, healthy tissues.

KW - Artificial transcription factor

KW - Cancer

KW - Hypoxia

KW - Hypoxia-response element

KW - Vascular endothelial growth factor A

KW - Zinc-finger protein

UR - http://www.scopus.com/inward/record.url?scp=78149468563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149468563&partnerID=8YFLogxK

U2 - 10.1007/s12033-010-9288-z

DO - 10.1007/s12033-010-9288-z

M3 - Article

VL - 46

SP - 134

EP - 139

JO - Molecular Biotechnology

JF - Molecular Biotechnology

SN - 1073-6085

IS - 2

ER -